Novartis versus India patent case postponed to July 10 Pharma Times Last week, Roche said it would offer significantly cheaper, locally-branded versions of its two cancer blockbusters, Herceptin (trastuzumab) and MabThera (rituximab) in India by early next year, as part of a deal with generics firm Emcure ... |
